A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Latest Information Update: 28 Oct 2020
At a glance
- Drugs 2 fluorofucose (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Seagen
- 17 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 08 Apr 2019 Planned End Date changed from 1 Aug 2022 to 1 Jun 2019.
- 08 Apr 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2019.